Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis

Yale Journal of Biology and Medicine

Volumn 84, Issue 4, 2011, Pages 361-369

  Smith, Jonathan Paul ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

ATDs; Chemotherapy; Drug resistant tuberculosis; MDR TB; Nanoparticle; Tuberculosis

Indexed keywords

AMIKACIN; CAPREOMYCIN; ETHAMBUTOL; ISONIAZID; KANAMYCIN; NANOPARTICLE; NANOSPHERE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; CAUSAL ATTRIBUTION; DEPRESSION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; DRUG TISSUE LEVEL; DRUG UPTAKE; FATIGUE; HEARING LOSS; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; LOWEST INCOME GROUP; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NANOTECHNOLOGY; NAUSEA; NEUROPATHY; NONHUMAN; PARTICLE SIZE; PATHOGENESIS; POVERTY; REVIEW; SUSTAINED DRUG RELEASE; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MICROBIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; NANOPARTICLES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84863013282     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Global Tuberculosis Control: Epidemiology, Strategy, Financing. Geneva: World Health Organization; 2009. Report No.: WHO/HTM/TB/2009.411.
2. Treatment of Drug Susceptible Tuberculosis Disease in Persons Not Infected with HIV. TB Elimination Factsheet: Centers for Disease Control and Prevention (CDC); 2003.
3. Multidrug and extensively drug resistant TB: 2010 Global Report on surveillance and response. Geneva: World Health Organization; 2010.
4. Karim SSA, Churchyard GJ, Karim QA, Lawn SD. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet. 2009;374(9693):921-33.
5. Kreuter J. Nanoparticles as drug delivery system. In: Nalwa HS, editor. Encyclopedia of Nanoscience and Nanotechnology. New York: American Science Publishers; 2004. p. 161-80.
6. Jarlier V, Nikaido H. Mycobacterial cell wall: Structure and role in natural resistance to antibiotics. FEMS Microbiology Letters. 1994;123(1-2):11-18.
7. Brennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis. 2003;83(1-3):91-7.
8. Daffe M, Draper P. The Envelope Layers of Mycobacteria with Reference to their Pathogenicity. In: Poole RK, editor. Advances in Microbial Physiology. Academic Press; 1997. p. 131-203.
9. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. State of the art series. Drug-resistant tuberculosis. Edited by Chiang C-Y. Int J Tuberc Lung Dis. 2009;13(11):1320-30.
10. Shoeb HA, Bowman BU, Ottolenghi AC, Merola AJ. Peroxidase-mediated oxidation of isoniazid. Antimicrob Agents Chemother. 1985;27(3):399-403.
11. Rozwarski DA, Grant GA, Barton DHR, Jacobs WR, Sacchettini JC. Modification of the NADH of the Isoniazid Target (InhA) from Mycobacterium tuberculosis. Science. 1998;279(5347):98-102.
12. Johnsson K. Studies on the mechanism of action of isoniazid and ethionamide in the chemotherapy of tuberculosis. J Am Chem Soc. 1995;117(17):5009.
13. Scorpio A. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med. 1996;2(6):662.
14. Zhang Y. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother. 2003;52(5):790.
15. Mikusova K. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob Agents Chemother. 1995;39(11):2484.
16. Zainuddin ZF. Does Mycobacterium tuberculosis have plasmids? Tubercle. 1990;71(1):43.
17. Telenti A, Imboden P, Marchesi F, Matter L, Schopfer K, Bodmer T, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993;341(8846):647-51.
18. Management of MDR-TB: A Field Guide. Italy: World Health Organization/Partners in Health; 2009. Report No.: WHO/HTM/TB/2008.402a.
19. Andrews JR, Gandhi NR, Moodley P, Shah NS, Bohlken L, Moll AP, et al. Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. J Infect Dis. 2008;198(11):1582.
20. Zajtchuk R. New technologies in medicine: biotechnology and nanotechnology. Diseasea-Month. 1999;45(11):453-95.
21. Florence AT. Issues in Oral Nanoparticle Drug Carrier Uptake and Targeting. J Drug Target. 2004;12(2):65-70.
22. Pandey R, Ahmad Z. Nanomedicine and experimental tuberculosis: facts, flaws, and future. Nanomedicine. 2011;7(3):259-72.
23. Perugini P, Simeoni S, Scalia S, Genta I, Modena T, Conti B, et al. Effect of nanoparticle encapsulation on the photostability of the sunscreen agent, 2-ethylhexyl-pmethoxycinnamate. Int J Pharm. 2002;246(1-2):37-45.
24. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14(5):1310-6.
25. Govender T, Ojewole E, Naidoo P, Mackraj I. Polymeric Nanoparticles for Enhancing Antiretroviral Drug Therapy. Drug Delivery. 2008;15(8):493-501.
26. Pandey R, Zahoor A, Sharma S, Khuller GK. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis. 2003;83(6):373-8.
27. Sharma A, Pandey R, Sharma S, Khuller GK. Chemotherapeutic efficacy of poly (dl-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int J Antimicrob Agents. 2004;24(6):599-604.
28. Bummer PM. Physical Chemical Considerations of Lipid-Based Oral Drug Delivery-Solid Lipid Nanoparticles. Crit Rev Ther Drug Carrier Syst. 2004;21(1):1-20.
29. Florence AT, Hussain N. Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv Drug Deliv Rev. 2001;50(Suppl 1):S69-S89.
30. Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med. 2005;172(12):1487-90.
31. Pandey R. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. J Antimicrob Chemother. 2004;54(1):266.
32. Sung JC. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob Agents Chemother. 2009;53(4):1338.
33. Anisimova YV. Nanoparticles as antituberculosis drugs carriers: effect on activity against Mycobacterium tuberculosis in human monocyte-derived macrophages. Journal of Nanoparticle Research. 2000;2(2):165.
34. Kayser O, Olbrich C, Croft SL, Kiderlen AF. Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs. Parasitol Res. 2003;90(Suppl 2):S63-70.
35. Pinto-Alphandary H, Andremont A, Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int J Antimicrob Agents. 2000;13(3):155-68.
36. Barrow ELW. Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrob Agents Chemother. 1998;42(10):2682.
37. Fawaz F, Bonini F, Maugein J, Lagueny AM. Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: pharmacokinetics and in vitro antimicrobial activity. Int J Pharm. 1998;168(2):255-9.
38. Addressing Poverty in TB control. Geneva: World Health Organization; 2005. Report No.: WHO/HTM/TB/2005.352.
39. Katiyar SK. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2008;12(2):139.
40. Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, et al. Clinical outcome of individualised treatment of multidrugresistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005;365(9456):318-26.
41. Pandey R. Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother. 2005;55(4):430.